Odile Tanguy-Boespflug
Expertise in
21
conditions

Odile Tanguy-Boespflug

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
21
conditions
Paris, FR 

Overview

Odile Tanguy-Boespflug practices in Paris, France. Ms. Tanguy-Boespflug is highly rated in 21 conditions, according to our data. Her top areas of expertise are Leukodystrophy, Spastic Paraplegia Type 2, Spinal Muscular Atrophy (SMA), and Pelizaeus-Merzbacher Disease.

Her clinical research consists of co-authoring 110 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Paris, France
Other Locations
Boulogne-billancourt, France
Robert, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Enrollment Status: Recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias
Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias
Enrollment Status: Completed
Publish Date: February 04, 2025
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
Evaluation of METAglut1 Diagnostic Test Performances in Patients With a Clinical Suspicion of GLUT1 Deficiency Syndrome
Evaluation of METAglut1 Diagnostic Test Performances in Patients With a Clinical Suspicion of GLUT1 Deficiency Syndrome
Enrollment Status: Completed
Publish Date: December 01, 2022
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)
A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)
Enrollment Status: Terminated
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Enrollment Status: Terminated
Publish Date: June 16, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

110 Total Publications

Human TBK1 deficiency: An expanded spectrum from autoinflammation to viral encephalitis.
Human TBK1 deficiency: An expanded spectrum from autoinflammation to viral encephalitis.
Journal: Journal of human immunity
Published: November 17, 2025

Frequently Asked Questions about Odile Tanguy-Boespflug

Is Odile Tanguy-Boespflug a top-rated expert for Leukodystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Odile Tanguy-Boespflug is classified as an Elite expert for Leukodystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Odile Tanguy-Boespflug participate in research or clinical trials?

Yes. Odile Tanguy-Boespflug has published 110 articles and abstracts on conditions like Leukodystrophy. You can view a list of Odile Tanguy-Boespflug's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tanguy-Boespflug's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 11 Advanced Conditions
View All 52 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile